Data / Drug companies / Shandong New Time Pharmaceutical Co., Ltd.
Shandong New Time Pharmaceutical Co., Ltd.: 31 products in the FDA NDC directory, labeler code 42677
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Shandong New Time Pharmaceutical Co., Ltd. (labeler code 42677) lists 31 products in the FDA National Drug Code Directory, covering 9 finished drugs by generic name. By type: 22 prescription drugs, 5 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on April 17, 2026.
The request: Watch Shandong New Time Pharmaceutical Co., Ltd. (FDA labeler code 42677): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 42677
- Products in commercial distribution
- 31
- Packages
- 37
- Finished drugs by generic name
- 9
- Prescription products
- 22
- Over the counter products
- 0
- Flagged as original packager
- 20 of 20 products that carry the flag
- Started marketing in the last 12 months
- 4
- Earliest marketing start
- November 21, 2006
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 22 | 71% |
| Bulk ingredients | 4 | 12.9% |
| Drugs for further processing | 4 | 12.9% |
| Bulk ingredients for compounding | 1 | 3.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 22 | 71% |
| Bulk ingredients | 5 | 16.1% |
| Drugs for further processing | 4 | 12.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Rosuvastatin calcium | 4 | 34 |
| Oseltamivir phosphate | 3 | 37 |
| Isosorbide mononitrate | 3 | 25 |
| Milrinone lactate | 3 | 12 |
| Rocuronium bromide | 2 | 25 |
| Sugammadex | 2 | 22 |
| Isoflurane | 2 | 5 |
| Oxaliplatin | 2 | 16 |
| Sevoflurane | 1 | 9 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 9 | 29% |
| Powder | 7 | 22.6% |
| Liquid | 5 | 16.1% |
| Tablet, film coated | 4 | 12.9% |
| Capsule | 3 | 9.7% |
| Tablet, extended release | 3 | 9.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| HMG-CoA Reductase Inhibitor | 4 |
| Neuraminidase Inhibitor | 3 |
| Nitrate Vasodilator | 3 |
| Phosphodiesterase 3 Inhibitor | 3 |
| General Anesthetic | 3 |
| Nondepolarizing Neuromuscular Blocker | 2 |
| Platinum-based Drug | 2 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Rosuvastatin Calcium | 42677-304 | Tablet, film coated | Generic drugs (ANDA) | April 17, 2026 |
| Rosuvastatin Calcium | 42677-303 | Tablet, film coated | Generic drugs (ANDA) | April 17, 2026 |
| Oxaliplatin | 42677-337 | Injection, solution | Generic drugs (ANDA) | January 15, 2026 |
| Oxaliplatin | 42677-336 | Injection, solution | Generic drugs (ANDA) | January 15, 2026 |
| Isoflurane | 42677-327 | Liquid | Generic drugs (ANDA) | November 4, 2025 |
| Isoflurane | 42677-326 | Liquid | Generic drugs (ANDA) | November 4, 2025 |
| Oseltamivir phosphate | 42677-322 | Capsule | Generic drugs (ANDA) | July 9, 2025 |
| Oseltamivir phosphate | 42677-321 | Capsule | Generic drugs (ANDA) | July 9, 2025 |
| Oseltamivir phosphate | 42677-320 | Capsule | Generic drugs (ANDA) | July 9, 2025 |
| Milrinone Lactate | 42677-338 | Injection, solution | Generic drugs (ANDA) | June 5, 2025 |
| Sugammadex | 42677-312 | Injection, solution | Generic drugs (ANDA) | May 1, 2025 |
| Sugammadex | 42677-311 | Injection, solution | Generic drugs (ANDA) | May 1, 2025 |
| Milrinone | 42677-107 | Powder | Bulk ingredients | March 24, 2025 |
| Rocuronium Bromide | 42677-310 | Injection, solution | Generic drugs (ANDA) | July 12, 2024 |
| Rocuronium Bromide | 42677-309 | Injection, solution | Generic drugs (ANDA) | July 12, 2024 |
| Isosorbide Mononitrate | 42677-306 | Tablet, extended release | Generic drugs (ANDA) | February 8, 2024 |
| Isosorbide Mononitrate | 42677-305 | Tablet, extended release | Generic drugs (ANDA) | February 8, 2024 |
| Sevoflurane | 42677-308 | Liquid | Generic drugs (ANDA) | August 18, 2023 |
| Milrinone Lactate | 42677-314 | Injection, solution | Generic drugs (ANDA) | January 23, 2023 |
| Milrinone Lactate | 42677-313 | Injection, solution | Generic drugs (ANDA) | January 23, 2023 |
| Isosorbide Mononitrate | 42677-307 | Tablet, extended release | Generic drugs (ANDA) | April 29, 2022 |
| Orlistat | 42677-119 | Powder | Bulk ingredients | April 1, 2022 |
| Rosuvastatin Calcium | 42677-302 | Tablet, film coated | Generic drugs (ANDA) | January 22, 2022 |
| Rosuvastatin Calcium | 42677-301 | Tablet, film coated | Generic drugs (ANDA) | January 22, 2022 |
| Isoflurane | 42677-114 | Liquid | Bulk ingredients | January 1, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.